Compare LYEL & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYEL | PRE |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | 98 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.1M | 337.6M |
| IPO Year | 2021 | N/A |
| Metric | LYEL | PRE |
|---|---|---|
| Price | $13.01 | $19.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $30.60 | $30.50 |
| AVG Volume (30 Days) | 135.4K | ★ 257.3K |
| Earning Date | 05-13-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | $108.69 |
| Revenue Next Year | $8,712.13 | $58.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.49 | $7.18 |
| 52 Week High | $45.00 | $23.63 |
| Indicator | LYEL | PRE |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 50.33 |
| Support Level | $12.00 | $17.44 |
| Resistance Level | $13.88 | $21.81 |
| Average True Range (ATR) | 1.05 | 1.47 |
| MACD | 0.18 | -0.17 |
| Stochastic Oscillator | 54.44 | 35.12 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.